Sree M Lanka

Sree M Lanka's work focuses on genitourinary cancers, particularly prostate and urothelial (bladder) cancer, with an emphasis on using blood-based tests (circulating tumor DNA, or ctDNA) to monitor treatment response and predict outcomes for patients receiving immune checkpoint inhibitors and other targeted therapies. Related work also touches on blood disorders such as sickle cell anemia, hematologic malignancies, and COVID-19 immune responses in cancer patients. This research is largely clinical and translational, often presented as conference abstracts and case studies alongside full research papers.

Publication output was minimal before 2022, then sharply increased with a peak of 14 outputs in 2023, followed by a decline in 2024-2025, suggesting a burst of activity rather than steady long-term growth.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026